Patents by Inventor Robert Silverman

Robert Silverman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DEUTERATED CFTR MODULATORS
    Publication number: 20190284175
    Abstract: This invention relates to novel, deuterated forms of VX-661 and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating cystic fibrosis.
    Type: Application
    Filed: October 22, 2018
    Publication date: September 19, 2019
    Inventors: I. Robert SILVERMAN, Roger D. TUNG
  • Morphinan compounds
    Patent number: 10406155
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: September 10, 2019
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • 4-HYDROXYBUTYRIC ACID ANALOGS
    Publication number: 20190100484
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Application
    Filed: August 6, 2018
    Publication date: April 4, 2019
    Inventors: Roger D. Tung, Adam J. Morgan, I. Robert Silverman
  • MORPHINAN COMPOUNDS
    Publication number: 20190038618
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: July 16, 2018
    Publication date: February 7, 2019
    Inventors: Philip B. Graham, I. Robert Silverman
  • Deuterated CFTR modulators
    Patent number: 10196384
    Abstract: This invention relates to novel, deuterated forms of VX-661 and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating cystic fibrosis.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: February 5, 2019
    Assignee: Vertex Pharmaceuticals (Europe) Limited
    Inventors: I. Robert Silverman, Roger D. Tung
  • Morphinan compounds
    Patent number: 10022370
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: July 17, 2018
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • DEUTERATED VX-661
    Publication number: 20180111920
    Abstract: This invention relates to novel, deuterated forms of VX-661 and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating cystic fibrosis.
    Type: Application
    Filed: March 30, 2016
    Publication date: April 26, 2018
    Inventors: I. Robert SILVERMAN, Roger D. TUNG
  • DEUTERATED TIC10
    Publication number: 20180016277
    Abstract: This invention relates to novel imidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one compounds, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions alone or in combination with other therapeutics in the treatment of diseases and conditions that are beneficially treated by administering an inducer of the gene encoding tumor necrosis factor (TNF) related apoptosis-inducing ligand (TRAIL) superfamily member 10.
    Type: Application
    Filed: January 27, 2016
    Publication date: January 18, 2018
    Inventor: I. Robert Silverman
  • MORPHINAN COMPOUNDS
    Publication number: 20170281616
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: April 14, 2017
    Publication date: October 5, 2017
    Applicant: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • Deuterated momelotinib
    Patent number: 9776973
    Abstract: The present invention in one embodiment provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: October 3, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Robert Silverman
  • DEUTERATED DERIVATIVES OF RUXOLITINIB
    Publication number: 20170239254
    Abstract: The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
    Type: Application
    Filed: March 9, 2017
    Publication date: August 24, 2017
    Inventors: I. Robert Silverman, Julie F. Liu, Adam J. Morgan, Bhaumik Pandya, Scott L. Harbeson
  • Derivatives of pyrazole-substituted amino-heteroaryl compounds
    Patent number: 9707218
    Abstract: This invention relates to novel pyrazole-substituted amino-heteroaryl compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of anaplastic lymphoma kinase (ALK).
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: July 18, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Bhaumik A. Pandya, Craig E. Masse, Ian Robert Silverman, Roger D. Tung
  • DEUTERATED MOMELOTINIB
    Publication number: 20170144977
    Abstract: The present invention in one embodiment provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.
    Type: Application
    Filed: November 30, 2016
    Publication date: May 25, 2017
    Inventor: Robert Silverman
  • Morphinan compounds
    Patent number: 9655895
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: May 23, 2017
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • Deuterated momelotinib
    Patent number: 9518027
    Abstract: The present invention in one embodiment provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: December 13, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Robert Silverman
  • 4-HYDROXYBUTYRIC ACID ANALOGS
    Publication number: 20160326086
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Application
    Filed: April 11, 2016
    Publication date: November 10, 2016
    Inventors: Roger D. Tung, Adam J. Morgan, I. Robert Silverman
  • MORPHINAN COMPOUNDS
    Publication number: 20160287579
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a al receptor agonist that also has NMDA antagonist activity.
    Type: Application
    Filed: May 6, 2016
    Publication date: October 6, 2016
    Inventors: Philip B. Graham, I. Robert Silverman
  • Morphinan compounds
    Patent number: 9340512
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: May 17, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman
  • Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof
    Patent number: 9315483
    Abstract: The present invention provides a convenient and efficient process for the synthesis of d2-benzo[d][1,3]dioxoles.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: April 19, 2016
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Andrew D. Jones, Robert E. Zelle, I. Robert Silverman
  • Morphinan compounds
    Patent number: 9266837
    Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: February 23, 2016
    Assignee: Concert Phamaceuticals, Inc.
    Inventors: Philip B. Graham, I. Robert Silverman